Data / Form D filings / RNAV8 BIO, INC.
RNAV8 BIO, INC.: Form D filings
RNAV8 BIO, INC., a biotechnology company in Laguna Niguel, CA, filed 4 Form D notices with the SEC between 2023 and 2025. The latest, on March 17, 2025, reports $2 million sold of a $3 million offering to 42 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 29851 WEATHERWOOD, Laguna Niguel, CA, 92677
- Phone
- (949) 637-2100
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2022
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1960745
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 17, 2025 | Amendment | $3,000,000 | $2,013,880 | $986,120 | 42 | May 9, 2022 | sec.gov |
| Jun 26, 2023 | Amendment | $2,000,000 | $999,500 | $1,000,500 | 11 | May 9, 2022 | sec.gov |
| Jan 4, 2023 | Amendment | $2,000,000 | $599,500 | $1,400,500 | 11 | May 9, 2022 | sec.gov |
| Jan 4, 2023 | New notice | $2,000,000,000 | $599,500 | $1,999,400,500 | 11 | May 9, 2022 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Devan Shah | Executive Officer, Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Mar 17, 2025 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what RNAV8 BIO, INC. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.